No Data
Akeso, Inc.'s (HKG:9926) Shareholders Might Be Looking For Exit
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.
Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
Guolian's investment strategy for the CSI SWS Health Care index in 2025: Look at space for incremental growth and at structure for existing assets.
Looking ahead to the CSI SWS Health Care index in 2025, from the perspective of incremental growth, attention should be paid to the long-term development of three major areas: medical insurance, self-paying, and overseas expansion; from the perspective of existing growth, attention should be paid to the essence of medicine and Medical.
Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference
MayFlower : It was predictable..
Midnite52 : yep